During the COVID-19 pandemic, many people have more or less consciously come into contact with microfluidics in the form of rapid tests for the first time. However, hardly anyone knows that microfluidics plays a significant role in around 70% of all medical decisions and that modern medical molecular diagnostic methods are based on it. Similar to microelectronics, circuit concepts, so-called labs-on-a-chip (LoC), have great automation potential for microfluidic processes. However, their widespread use is being held back by the fact that it is currently not possible to combine all system components on a chip. Instead, they are complex computer-controlled microelectromechanical systems (MEMS) without feedback to the (bio)chemical information carriers, which are too expensive or too inefficient for many potential applications. Microfluidic integrated circuits based on smart materials, so-called chemofluidic LoCs, have a completely different functional principle that solves key problems of MEMS LoCs. The smart material components are self-powered by the chemical energy of the process liquids and have feedback functions to the process-relevant (bio)chemicals. Combined into logical circuits, the smart material components control the complex circuit processes autonomously thanks to their material-inherent sensor-actuator functions. They therefore completely replace the complex MEMS-LoC systems in functional terms, despite being completely electronics-free. The central components are chemofluidic transistors, which have decision-making functions for process-relevant chemical and physical parameters. We introduce two basic types of chemofluidic transistors, the membrane-isolated chemofluidic volume-phase transition transistor (MIS-CVPT) and the chemofluidic volume-phase transition transistor (CVPT) [1], and discuss helpful analogies to microelectronic transistor concepts. We then outline the fundamentals of discrete and analogue chemofluidic circuits (Figures 1 and 2) [2], [3] and dicuss basic fabrication concepts of chemofluidic circuits printing [4]. Using specific point-of-care tests, including a rapid test for respiratory infections, we discuss the potential of chemofluidics and demonstrate that, despite its early stage of development, chemofluidics is already relevant to practice. We show how the test protocols to be automated are translated into specific circuit designs. We then present how the chemofluidic circuits autonomously and feedback-controlled by the process media containing the detection chemistry and the patient samples calculate and execute the specific analysis procedure. We also compare the results obtained with the gold standards.